Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01298011 · ClinicalTrials.gov registry record · Phase 2
Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer
A Phase 2 study, sponsored by Pancreatic Cancer Research Team.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT01298011: Completed Phase 2 study, sponsored by Pancreatic Cancer Research Team.
NCT01298011 is a Phase 2 study that has completed, run by Pancreatic Cancer Research Team. The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01298011, a Phase 2 study, has completed, sponsored by Pancreatic Cancer Research Team.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The main purpose of this research study is to evaluate whether Abraxane and gemcitabine are effective in treating patients with operable pancreatic cancer.
Interventions
- DRUG Gemcitabine and Abraxane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2011-05 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
What the finished NCT01298011 record still lists
NCT01298011 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 1 intervention - of which Gemcitabine and Abraxane is the first listed.
NCT01298011 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01298011 about?
NCT01298011 is a clinical study titled "Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer". The main purpose of this research study is to evaluate whether Abraxane and gemcitabine are effective in treating patients with operable pancreatic cancer.
What is the current status of trial NCT01298011?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2011-05. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01298011?
The interventions under investigation include: Gemcitabine and Abraxane (DRUG).
Who is sponsoring clinical trial NCT01298011?
This trial is sponsored by Pancreatic Cancer Research Team, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01298011's enrollment target sits among peer trials
25 1719th of 2000 higher than 245 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia